In this edition of Founder Thesis, Akshay Datt talks with Dr. Anand Anandkumar, CEO and MD of Bugworks Research Inc., a remarkable drug discovery company focused on developing novel broad-spectrum antibiotics and immunotherapies that stand to transform the healthcare ecosystem worldwide.
A veteran in the semiconductor industry with almost two decades of experience, Dr. Anandkumar wears many hats. To mention a few, he is the Vice President of the India Biotech Association & one of the founding members of the India Electronics and Semiconductor Association (IESA).
In 2005, he founded Cellworks which has significantly increased the success rate of cancer treatments by customizing therapy choices. An offshoot of Cellworks, Bugworks originated from the deep resolve to eradicate secondary bacterial infections, a major public health threat in terms of mortality.
Tune in to this episode to hear Dr. Anandkumar speak about how Bugworks has taken a unique path in drug discovery as it attempts to fight the war against rising antibacterial resistance.
What you must not miss!
- Current drug development challenges
- Monetizing drug combination therapies
- AMR and superbugs
